Drugs for COPD and Asthma

Edit Answers
12345678910111213141516171819202122232425
Across
  1. 3. Patients who have used glucocorticoids for a long period of time may require increased doses during these times
  2. 4. This inhalation device uses small particles to ensure greater delivery of a drug
  3. 6. This type of suppression is of particular concern with glucocorticoid use
  4. 13. Beta 2 Adrenergic Agonists promote bronchodilation by activating the beta 2 receptors in the _______________ muscle of the lungs
  5. 16. Glucocorticoids must be discontinued ______________
  6. 17. Theophylline toxicity is treated with this agent
  7. 18. Side effect of inhaled forms of glucocorticoids
  8. 22. Growth suppression in this population is an adverse effect of glucocorticoid use
  9. 24. Glucocorticoids should be dosed on this type of schedule
  10. 25. The mechanism of action for glucocorticoids is to suppress ______________
Down
  1. 1. First-line therapy for management of inflammatory components of asthma
  2. 2. inhaled long acting beta 2 agonists are taken on a ___________ schedule
  3. 5. this methylxanthine is no longer recommended for the treatment of COPD
  4. 7. Adverse effect of Leukotriene receptor antagonists
  5. 8. This long acting anticholinergic drug is used maintenance therapy for COPD patients
  6. 9. Leukotriene receptor antagonists work by suppressing the effects of ___________________
  7. 10. a common systemic adverse effect of Beta 2 Adrenergic Agonists
  8. 11. Delivery method for Ipratropium
  9. 12. One of the advantages of inhalation therapy is that systemic effects are __________________
  10. 14. This form of glucocorticoids should only be used for patients with moderate to severe persistent asthma or management of acute COPD/asthma exacerbations
  11. 15. this inhaled mast cell stabilizer works by stabilizing the cytoplasmic membrane of mast cells while also inhibiting eosinophils and macrophages and other inflammatory cells
  12. 19. this class of medications provides symptomatic relief but does not alter the underlying inflammation
  13. 20. inhaled short acting beta 2 agonists are taken on a ___________ schedule
  14. 21. This Leukotriene receptor antagonist has the highest risk for hepatotoxicity
  15. 23. anticholinergic drugs work to improve lung function by blocking _______________ receptors in the bronchi